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ABSTRACT  
The scaffold protein Spinophilin (SPN) is a regulatory subunit of phosphatase1a located 
at 17q21.33. This region is frequently associated with microsatellite instability and LOH 
containing a relatively high density of known tumor suppressor genes, including 
BRCA1. Several linkage studies have suggested the existence of an unknown tumor 
suppressor gene distal to BRCA1. Spn may be this gene but the mechanism through this 
gene make its contribution to cancer has not been described. In this study, we aimed to 
determine how loss of Spn may contribute to tumorigenesis. We explored the 
contribution of SPN to PP1a-mediated Rb regulation. We found that the loss of Spn 
downregulated PPP1CA and PP1a activity, resulting in a high level of phosphorylated 
Rb, and increased ARF and p53 activity. However, in the absence of p53, reduced 
levels of SPN enhanced the tumorigenic potential of the cells. Furthermore, the ectopic 
expression of SPN in human tumor cells greatly reduced cell growth. Taken together, 
our results demonstrate that the loss of Spn induces a proliferative response by 
increasing Rb phosphorylation, which in turn activates p53, thereby, neutralizing the 
proliferative response. We suggest that Spn may be the tumor suppressor gene located at 
17q21.33 acting through Rb regulation. 
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INTRODUCTION 
The Spinophilin (Spn, Neurabin II, PPP1R9B) locus is located on chromosome 17 at 
position 17q21 which is in a cytogenetic area frequently associated with microsatellite 
instability and loss of heterozygosity (LOH). This region has a relatively high density of 
tumor suppressor genes, including known (e.g., BRCA1 and NME1), putative (e.g., JUP 
and Prohibitin), and unidentified candidate tumor suppressor genes that are located 
distal to the BRCA1 locus. Most of the studies examining the 17q21 region have focused 
on BRCA1, which exhibits LOH at a variable frequency depending on the type and stage 
of the tumor, and as such, the 17q21 region has been extensively studied in breast 
carcinomas 1-3. However, some studies have suggested the presence of an unknown 
tumor suppressor gene in the area that includes the Spn locus. LOH at 17q21.3 
involving the BRCA1 locus has been observed in breast, ovarian, prostate, colorectal, 
gastric, renal, and lung carcinomas, as well as in salivary gland carcinosarcomas, an 
extremely aggressive neoplasm. This region contains both NME1 and Spn, which are 
only 1 Mb apart. Extensive LOH mapping in primary lung carcinomas 4 using 15 highly 
polymorphic markers revealed the highest LOH value (53% loss) with the D17S588 
marker, which is located within the Spn locus. However, neighboring tumor suppressor 
genes, including BRCA1, were not significantly affected (6–13% LOH). Furthermore, 
previous classic cytogenetic studies that investigated the genetic association of breast 
and ovarian cancers with the 17q region have suggested the presence of a tumor 
suppressor gene located distal to BRCA1 5-7. The maximum LOD scores obtained for 
D17S588 were 5.44 in an Edinburgh study of 15 families 8 and 21.68 in an extensive 
analysis of 271 families with breast and breast/ovarian cancer 9-10, indicating the 
importance of this region in cancer pathology. Another study examining the correlation 
between p53 abnormalities and allelic loss of BRCA1, BRCA2, and adjacent loci in 
breast cancer found a strong correlation between p53 mutations and the specific loss of 
the Spn locus 1, 11.  
Although these studies suggest the existence of an unknown tumor suppressor in this 
region, no biological function for Spn has been reported that would explain the benefits 
that a tumor cell might gain by losing this gene. Furthermore, the correlation between 
p53 mutations and the specific loss of the Spn locus is not understood. The focus of this 
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study was to determine how the loss of Spn may contribute to tumorigenesis and the 
role of p53 mutations in this process. 
Two independent laboratories have shown that SPN interacts with protein phosphatase 1 
(PP1) and F-actin 12-13. SPN contains a number of distinct domains that govern protein-
protein interactions, including two F-actin domains, three potential Src homology 3 
domains, a receptor and a PP1-binding domain, a PDZ domain, three coiled-coil 
domains, and a potential leucine/isoleucine zipper motif 14. While more than 30 SPN-
binding partners have been discovered, including cytoskeletal and cell adhesion 
molecules, enzymes, guanine nucleotide exchange factors (GEFs), regulators of G-
protein signaling, membrane receptors, ion channels, and the tumor suppressor ARF 14, 
the physiological relevance of some of these interactions remains undetermined. The 
structure of SPN suggests that it functions as a multifunctional scaffold protein that 
regulates both membrane and cytoskeletal processes. SPN mediates important functions 
in the nervous system, where it has been implicated in regulating spine morphology and 
density, synaptic plasticity, and neuronal migration. SPN also regulates seven-
transmembrane receptors and may link these receptors to intracellular mitogenic 
signaling events that are dependent on p70S6 kinase and Rac G protein-GEF. 
Importantly, a role for SPN in cell growth has also been demonstrated, and this effect is 
enhanced by the interaction between SPN and ARF 15. Another SPN-interacting 
molecule is doublecortin, an actin-binding protein with an established role in the 
subcellular targeting of PP1 13, 16-17. SPN enhances PP1-mediated dephosphorylation of 
Ser297 in doublecortin 18 and its localization to the cytosol 19-20. One of the most 
important PP1 target proteins is Rb, the phosphorylated product of the retinoblastoma 
gene that is essential in cell cycle regulation 21. The targeting of Rb by PP1 contributes 
to the dephosphorylation and subsequent activation of Rb, shutting down the G1/S 
phases of the cell cycle 21-22. Furthermore, the PP1a-mediated dephosphorylation of Rb 
contributes to the senescent phenotype induced by oncogenic Ras 23 and the constitutive 
inactivation of Rb by maintaining highly phosphorylated Rb contributes to cell cycle 
deregulation and tumorigenesis 24-26. Therefore, SPN may contribute to tumorigenesis 
by regulating the functions of PP1 and/or Rb.  
This study aimed to elucidate the molecular mechanisms that could mediate Spn loss-
induced tumorigenesis, focusing on the SPN-PP1-Rb complex. We found that the loss 
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of Spn correlated with a reduced level of PPP1CA, which in turn maintained an elevated 
level of Rb. This effect contributed to a functional increase in p53 activity through 
ARF. However, in the absence of p53, SPN enhanced the tumorigenic properties of the 
cells. 
RESULTS 
The absence of Spn contributes to Rb deregulation by maintaining a low PPP1CA 
level and PP1 phosphatase activity. 
Because SPN binds to PPP1CA, thereby contributing to the regulation of PP1a activity, 
we first measured the effect of loss of Spn on PPP1CA expression. We generated mouse 
embryonic fibroblasts (MEFs) from Spn KO mice (Spn(-/-)) 18 and measured their 
PPP1CA level. An analysis of more than 20 pairs of wild-type (WT) and Spn (-/-) MEF 
clones demonstrated that Spn (-/-) cells contained 40% less PPP1CA protein (Figure 1A 
and 1B). Despite the parallel isolation of the MEF clones (i.e., all Spn-null clones were 
compared to their WT sibling clones at the same growth stage and passage), their 
PPP1CA levels seemed to be heterogeneous, perhaps due to variations in other 
PPP1CA-binding proteins. To determine whether the loss of Spn also affected the 
PPP1CA level under stress conditions, we expressed oncogenic Ras in the cells; this has 
previously been reported to increase the PPP1CA level 23, 27. The expression of 
oncogenic Ras induced a 50% increase in the PPP1CA level in the WT MEFs, but not in 
the Spn (-/-) MEFs (Figure 1C and 1D). We also observed that the expression of 
oncogenic Ras resulted in a similar increase in the SPN protein level in the WT MEFs 
(Figure 1C), suggesting that SPN and PPP1CA may be co-regulated and may both 
contribute to the regulation of PP1 activity. To further confirm this hypothesis, we 
aimed to determine whether the loss of SPN altered PP1a activity as a result of the 
reduced PPP1CA level. We quantified the PP1 activity as the difference in activity 
measured following treatment with 2.5 nM and 2.5 µM okadaic acid 28. We observed 
that PP1 phosphatase activity also decreased in the Spn-null cells in parallel with 
PPP1CA protein level, and this decrease was not reversed following the expression of 
oncogenic Ras (Figure 1E and 1F). To explore the mechanisms underlying the reduced 
PPP1CA level in Spn-null cells, we performed similar experiments in the presence of 
the proteasome inhibitor MG132. In the absence of proteasome-mediated degradation, 
the PPP1CA expression level and PP1 activity did not decrease in the absence of Spn 
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(Figure 1G and 1H). These results suggest that SPN may regulate the stability of 
PPP1CA, thereby regulating the activity of PP1a. 
To evaluate whether the decrease in PP1 activity has physiological significance, we 
measured the extent of Rb phosphorylation in the absence of SPN. Furthermore, 
because Rb phosphorylation controls S phase entry, we also examined whether the Rb 
phosphorylation correlated with alterations in the cell cycle. The cells were serum 
starved for 24 hrs to induce Rb dephosphorylation and growth arrest. The cells were 
then restimulated with 10% serum, and Rb phosphorylation was analyzed at different 
time points. In the WT cells, Rb was fully dephosphorylated up to 8 hrs after 
restimulation (Figure 2A and B), correlating with entry into S phase (Figure 2C). The 
Spn-null MEFs exhibited low, but detectable, levels of pRb even in the absence of 
serum, indicating reduced PP1 activity. Furthermore, 16 hr post-stimulation, the level of 
pRb doubled in the Spn-null MEFs (Figure 2A and B), correlating with the earlier entry 
of the cells into S phase (Figure 2C). In the absence of SPN, we detected both increased 
basal expression and stronger induction of Cyclin A, a transcriptional target of E2F1 
activation, following serum restimulation (Figure 2D and 2E), confirming the increased 
pRb phosphorylation. The higher level of pRB in the Spn-null MEFs also contributed to 
increased apoptosis in the Spn(-/-) MEFs upon p53 activation by DNA-damaging agents 
(Supplementary Figure 1).  
These results clearly demonstrate that, in the absence of SPN, PP1 exhibits reduced 
phosphatase activity, resulting in an elevated level of pRb.  
 
The absence of Spn contributes to genetic alterations during MEF immortalization. 
Several alterations occur during MEF immortalization, resulting in the release from 
senescence. These mutations tend to eliminate the G1-phase arrest imposed by 
senescence. Most commonly, MEF immortalization results from the loss of the INK4a 
locus or p53 mutations 29-31. The INK4a locus contains two genes, p16INK4a 32, an 
inhibitor of CDKs that is upregulated during senescence and contributes to Rb 
dephosphorylation 33, and p19ARF, an MDM2 regulator that contributes to p53 
activation 34-35.  
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We reasoned that if the Spn-null MEFs exhibited alterations in the Rb pathway, there 
would be no selective pressure to mutate p16INK4. To confirm this hypothesis, we 
generated multiple clones from WT (+/+), heterozygous (+/-), and Spn-null (-/-) MEFs 
and immortalized these cells using standard 3T3 protocols. The loss of Spn did not 
preclude the cells from entering senescence, and this response occurred with kinetics 
similar to WT cells 36. However, Spn deficiency did affect the pattern of genetic 
alterations that occurred during MEF immortalization. Approximately 30% of the WT 
immortalized MEFs clones exhibited decreased p16INK4 expression, and 50% of the 
clones carried p53 mutations. However, neither the heterozygous nor the Spn-null (-/-) 
MEFs lost p16INK4a expression (Figure 3). All Spn-null (-/-) MEF clones were 
immortalized through mutations in p53 (Figure 3). All of the data regarding p53 
mutations that were detected based on the stabilization of p53 were confirmed by 
sequencing p53 mRNA (data not shown).  
The lack of Spn contributes to increased p53 activity. 
The lack of SPN seemed to promote p53 mutations in MEFs during immortalization, 
suggesting a functional relationship between SPN and p53. In addition, it has been 
shown that low levels of Rb activity activate the E2F family of transcription factors, 
which in turn activate p19ARF, thereby contributing to p53 upregulation 37-39,40. To 
explore this possibility, we first tested the effect of shRNA-mediated SPN silencing in 
cells expressing the Val135 thermosensitive p53 mutant (p53(-/-) ts cells) 23 (Figure 
4A). Switching the cultures to 32°C resulted in growth arrest, allowing only a small 
number of colonies to escape the arrest and to grow slowly. Silencing of SPN enhanced 
the observed p53-induced growth arrest in these cells. We then determined the p53 level 
in Spn-null MEFs. The Spn-null MEFs exhibited a slightly elevated level of p53, 
resulting in an elevated level of its downstream target p21waf1 (Figure 4B). Following 
induction of DNA damage with etoposide, a topoisomerase inhibitor, the increase in the 
p53 and p21waf1 levels were more significant in Spn-null MEFs when compared to WT 
cells (Figure 4B).  
Next, we aimed to determine the importance of the increased p53 levels induced by the 
loss of Spn to the tumor physiology. 3-MC is a mutagen that induces tumor formation in 
a p53 mutation–dependent manner 41. The addition of 3-MC enhanced the p53 response 
more significantly in Spn-null MEFs than in WT MEFs (Figure 4C). As expected, the 
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loss of Spn delayed the onset of tumorigenesis, increasing the survival of WT mice 
(Figure 4D). However, in mice with reduced p53 levels (i.e., heterozygous for p53), the 
loss of Spn did not increase the survival rate (Figure 4E). We could not perform these 
experiments in p53-null;Spn(-/-) or p53-null;Spn(+/-) mice due to their rapid death days 
after birth (data not shown). Taken together, our data suggest that the loss of Spn 
increases the activity of p53. 
The increased p53 activity observed in Spn-null MEFs seemed to be dependent on 
PPP1CA, as PPP1CA overexpression in Spn-null MEFs abolished this increase (Figure 
5A and supplementary figure 3). Ectopic expression of PPP1CA induced growth arrest. 
Among the resistant clones the doubling time was similar to parental cells expressing only 
vector (data not shown). In these clones we measured PPP1CA levels (supplementary figure 4) 
and we found that PPP1CA levels are only slightly increased. In these cells DNA-damage 
treatments induce p53 stabilization but the enhancement of the signal observed in the absence of 
Spn is loss (Figure 5A).  In addition, the increased p53 activity was also dependent on 
p19ARF. First, Spn-null MEFs exhibited increased p19ARF activation following 
expression of oncogenic Ras when compared to WT MEFs (Figure 5B). Furthermore, 
Spn-null MEFs expressing a p19ARF-specific shRNA did not demonstrate enhanced 
p53 activation following expression of oncogenic Ras when compared to the controls 
(Figure 5C and 5D), confirming that p19ARF mediates the increased p53 levels 
observed in Spn-null MEFs. However, we were unable to detect a physical interaction 
between SPN and p19ARF (Figure 5E and data not shown). 
Our overall interpretation of these results is that the loss of Spn leads to Rb inactivation 
and the further sequential activation of E2F, ARF, and p53. Therefore, p53 plays rate-
limiting, pivotal tumor suppressor role and must be mutated when SPN is non-
functional in order for cells to become transformed. 
The absence of Spn enhances the tumorigenic properties of p53-null cells. 
Next, we aimed to determine the effects of p53 deficiency on Spn-null cells. To this end, 
we measured their ability to potentiate the p53-null phenotype. First, we grew MEFs 
expressing the thermosensitive p53 mutant (p53(-/-)ts) at 39°C, thereby inactivating 
p53. Under these conditions, the shRNA-mediated silencing of SPN increased cell 
colony formation (Figure 6A). Additionally, the loss of SPN also enhanced the growth 
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of the MEFs (Figure 6B) by decreasing doubling time, and their growth recovery after 
serum starvation and restimulation (Figure 6C). Finally, the transfection of MEFs with 
the Ras oncogene or a combination of E1A and Ras induced an increase in both the 
number and size of the foci in Spn-null MEFs compared to mock-transfected MEFs 
(Figure 6D). These results confirm that the loss of SPN in p53-deficient cells enhances 
the tumorigenic potential of the cells. 
The overexpression of SPN reduces tumor cell growth. 
Because reduced SPN levels increased the malignant potential of the tumor cells, we 
determined if SPN overexpression might affect the malignant behavior of tumor cells. 
To evaluate the effect of SPN overexpression, we transfected tumor cells with Spn 
cDNA. Overexpression of SPN significantly reduced the colony numbers in all of the 
tested cell lines (Figure 6E). This growth inhibitory effect is similar to the growth 
inhibition described for PPP1CA overexpression 23 and occurred in all tested cell lines 
regardless of their p53 and pRb status (Supplementary Table 1).  
DISCUSSION 
Spn has been proposed to be a tumor suppressor because of its association with the LOH 
detected in genomic linkage studies and because loss of Spn migth contribute to lung 
tumorigenesis 42. However, it is not clear how the loss of Spn might affect cellular 
behavior and contribute to tumorigenesis. In this study, we demonstrate that the loss of 
Spn affected the behavior of Rb through its ability to regulate the PPP1CA level and 
PP1a activity. The loss of Spn resulted in Rb inactivation and the subsequent activation 
of E2F, ARF, and p53. However, in the absence of p53, the elevated pRb level 
enhanced the tumorigenic potential of the cells (Supplementary Figure 2). In line with 
this behavior, SPN has been shown to bind to the PP1-doublecortin complex, inducing 
its dephosphorylation 43 and inhibiting anchorage-independent growth in glioma cells 44-
46
. In contrast, doublecortin-mediated growth repression is lost in the absence of Spn. 
SPN appears to function as a classic scaffolding protein with no intrinsic enzymatic 
activity. SPN binds both PPP1CA and PPP1CC, but only marginally binds to PPP1CB 
47
. SPN selectively interacts with PPP1CC in the spinal cord, and it has been suggested 
that this binding is at least in part responsible for the enrichment of PPP1CC at synapses 
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48
. Similarly, the binding of SPN to PPP1CA results in partial coupled regulation 
between SPN and PP1a, as lower levels of SPN led to decreased PPP1CA levels and 
PP1 activity. It has been recently shown that SPN is unstructured in its unbound form 
and binds PP1 through a folding-upon-binding mechanism, blocking one of the three 
putative substrate binding sites of PP1 without altering the active site 49.  
PP1 is one of the key eukaryotic serine/threonine phosphatases involved in mitotic 
dephosphorylation of both Rb and specific residues of p53 50. Our data suggest that the 
mild p53 activation observed in the absence of Spn is related to enhanced Rb 
phosphorylation and activation of E2F and p19ARF because eliminating p19ARF 
blocked the enhanced p53 activation induced by oncogenic stress (Figure 5). It is 
interesting to remark the increase in p19ARF observed in Spn null compared to WT 
MEFs (Fig 5B). This increase might be dependent on E2F1 activation by pRb 
phosphorylation, since ARF is a target of E2F1 transcription target 51. Unfortunately, we 
do not currently understand why p19ARF is not deleted with the same frequency that 
p53 is mutated in Spn-null MEFs. We can only speculate that the INK4 locus 
contributes to senescence through both p19ARF and p16INK4a gene activation52. 
p16INK4a contributes to senescence through Rb, therefore alleviating the Rb tension 
(by Spn loss), reducing the requirement for INK4 deletion. 
However, similar to PPP1CA overexpression 21,23, SPN overexpression resulted in 
growth inhibition in culture, independently of the status of Rb and p53. This may be due 
to PP1-target proteins other than Rb, whose phosphorylation is thought to enable cells 
to replicate DNA, such as DNApolα or TopoII 53,54. It is also possible that the other 
pocket proteins, p130 or p107, are involved in pRb null cells response to PPP1CA 
overexpression since these proteins may have partially redundant control of cell cycle 55.  
However, complete loss of PP1a is also deleterious for the cells 21, and only partial loss 
of activity has been associated with tumorigenesis 23. PP1 does not only regulate the cell 
cycle, and Rb is not its only substrate. Therefore, SPN loss would be expected to have 
pleiotropic effects that are not solely related to Rb, but which may be equally important 
for tumour cell growth/survival54. 
The combination of Spn loss and p53 deficiency resulted in greatly enhanced 
tumorigenic properties in the cells. These results can be extended to a mouse model: we 
have shown that Spn KO mice exhibit increased cellular proliferation in the mammary 
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ducts, which translates to an increase in benign mammary lesions. In addition, the loss 
of Spn in combination with mutant p53 resulted in a large increase in the number of 
mammary carcinomas, confirming the functional relationship between p53 and SPN 36. 
Our data provide a functional explanation to several cancer studies that found a strong 
correlation between p53 mutations and the specific loss of the Spn locus (47.1 % LOH) 
1, 11,42
. Again, SPN may be involved in tumorigenesis by functioning, in association with 
the loss of p53 activity, as a tumor suppressor.  
SPN is a regulator of PP1a, and our data strongly argue in favor of PP1a as an important 
tumor suppressor. The downregulation of PPP1CA, the catalytic subunit of PP1α, has 
been shown to maintain the hyperphosphorylated state of Rb, allowing cell growth 23. 
PPP1CA has been mapped to chromosome 11q13 56, and translocations involving 
breakpoints at 11q13 have been observed in lymphomas, chronic B cell lymphocytic 
leukemia, and multiple myeloma 57-58. Results from the analysis of human solid tumors 
suggest that one PPP1CA allele may be lost in a high proportion of carcinomas, such as 
kidney and colorectal cancer 23.  
In summary, our data demonstrate that the scaffold protein SPN is important for the 
correct regulation of PP1α and Rb and that its absence may contribute to tumorigenesis 
in the absence of p53 in vivo. Therefore, the loss of Spn may induce a proliferative 
response by increasing Rb phosphorylation that may also be considered an anti-
proliferative senescence response. However, the loss of p53 activity can, in turn, bypass 
this senescence, thereby enhancing the malignant phenotype. Therefore, we suggest that 
SPN may be a novel tumor suppressor, reinforcing the role of PP1α as a tumor 
suppressor. 
 
MATERIALS AND METHODS 
Cell culture, retroviral vectors and gene transfer. Cells were generated and 
characterized following the same experimental procedure described in 59-60. 3T3 protocol 
was conducted as previously described in 30. Temperature shifts and cell proliferation 
analysis were performed as described in 61-62. Proliferation Assays, were performed for 
MTT colorimetric read-out as previously described in 63. 
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Cells treatment with 3MC, Etoposide, doxorubicin and H2O2. Cells were seeded in 
six-well plates. Next day, cells at 50–75% confluence were treated with doxorubicin (0.4 
or 0.8 µg/ml), Etoposide (100 mM), 3-Methylcholantrene (10µM) or with 100 µM 
H2O2, or UCN01 (50, 100 y 200nM) during the indicated times. After this period of 
time, cells were harvested and proteins analyzed as described in western blot analysis.  
Growth in soft agar and foci formation. To measure the anchorage-independent 
growth and foci formation we follow a protocol described previously in 64. BrDu 
incorporation. Was adapted from the protocol provided in the BrdU cell proliferation 
assay from Exalpha Biologicals, Inc. (Maynard, MA 01754, USA) 
Cell cycle analysis was assessed using flow cytometry by propidium iodide (Sigma) 
staining as described in 65. A total of 10,000 size gated cells were analyzed by 
FACSCalibur (BD Biosciences). 
Design of shRNA against Spn. An shRNA against Spn was designed using the 
‘Ambion siRNA target finder’ and the ‘Qiagen siRNA design tool’ to choose the 
appropriate hairpin oligonucleotides, which were then cloned in a pRetrosuper vector. 
An shRNA against PPP1CA was described in 23. 
Generation, handling, and analysis of transgenic mice. All animal experiments were 
done under the experimental protocol approved by the Institutional Committee for Care 
and Use of Animals of the Spanish National Cancer Research Centre which complies 
with European legislation on the care and use of animals, NIH guidelines for the use of 
laboratory animals, and related codes of ethic practice. Spn KO generation and 
genotyping protocols are described in 18. p53 KO 66 mice were obtained from Jackson 
laboratories.  
 
Carcinogenic treatment with 3-Methylcholantrene (3MC). 3MC was dissolved in 
sesame oil at 10 mg/ml. cohorts of 20 mice between 3 and 5 months of age were 
intramuscularly injected with a dose of 1 mg of 3MC (100µl) or sesame oil only in the 
right back leg. Mice were examined weekly and sacrificed when the tumour grew to 1 
cm in diameter.  
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Western Blot analysis. Total protein was extracted, processed and analyzed by western 
blot as described previously 67. To detect the different proteins, membranes were 
hybridized with the following primary antibodies: anti-PP1  (protein phosphatase-1 ) 
from Calbiochem; anti-Rb: G3-245 from BD PharMingen; anti-pRb phosphorylated: 
anti-pRb(Ser807/811) from Cell Signalling ; anti- -tubulin: T9026 from Sigma. Anti-
Spinophilin: AB5669 from Chemicon; anti-p53: p53 FL 393 (sc-6243) from Santa Cruz: 
anti- p21: C-19 (sc-397) from Santa Cruz. Anti- CycA; sc-751 from Santa Cruz. Anti-
p16ink4a: (m-156) from Santa Cruz sc-1207. anti-p19ARF: ab80 from Abcam  
(104996). The membrane was then incubated with secondary antibody containing the 
horseradish peroxidase antimouse IgG (Promega, Germany) or antirabbit IgG 
(Calbiochem, San Diego CA), and developed with a detection system for 
chemiluminescence (Amersham Biosciences, UK). 
Protein phosphatase assays. PP1 activity was determined using standard procedures, 
as described by the vendor (Anaspec) [66]. PP activity was assayed using pNPP as a 
substrate, which detects both PP1 and PP2A activities. To selectively quantify PP1 
activity, we used 2.5 nM okadaic acid to selectively inhibit PP2A and 2.5 µM okadaic 
acid to inhibit PP1. We measured PP1 activity as the difference in activity measured at 
2.5 nM and 2.5 µM okadaic acid. The cell pellet was homogenized in extraction buffer 
(20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 10 mM EGTA, 15 mM β-mercaptoethanol, 
0.25 M sucrose, 0.3% Triton X-100, 5 µg/ml leupeptin, and 5 µg/ml aprotinin) and 
centrifuged to produce a soluble supernatant. The PP activity in the cleared supernatant 
was determined by measuring the absorbance at 405 nM. The incubation for 
determining PP activity was 10 min, and each assay contained 5 µg of protein from the 
cell extracts, as determined using the Bio-Rad assay (Bio-Rad, Hercules, CA).With 
these conditions, the PP activity was linear. 
Statistical analysis. All statistics were analyzed using the SPSS statistical package 
(version 13.0 for Windows). A p value less than 0.05 was considered statistically 
significant.  
 
Immunostaining and confocal analysis for co-localization was performed as 
previously indicated in 68. The nuclei were stained with Hoechst 33258, for 3 min at 
room temperature prior to mounting with mowiol (Calbiochem). Images were 
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collected by confocal laser microscopy (model TCS-SP2-AOBS, Leica, Germany). 
Antibodies used were: Anti-Spinophilin: AB5669 from Chemicon; anti-p19ARF: ab80 
from Abcam  (104996); anti-p14ARF ab80 from Abcam  (104996).  
 
 
 
Figure Legends 
 
Figure 1. Loss of Spn affects Rb phosphorylation by decreasing the PPP1CA level. 
A) Spn-null MEFs express a lower level of PPP1CA. MEFs from Spn KO mice and WT 
littermates were grown, and protein was extracted from the cells after the same number 
of population doublings. PPP1CA expression was examined using western blot. Three 
independent Spn-null MEF clones and three WT clones out of twenty that were 
analyzed for each genotype are shown. B) Quantification of PPP1CA in Spn-null MEFs. 
The PPP1CA level in 20 Spn-null clones and 20 WT clones was quantified and 
normalized to the tubulin level in each clone. The PPP1CA levels in the Spn-null clones 
were compared to the PPP1CA levels in the WT clones using an ANOVA. C) PPP1CA 
expression in Spn-null MEFs is not increased following expression of oncogenic Ras. 
MEFs from Spn KO mice or WT littermates were grown and at passage two, infected 
with a retrovirus expressing Hras-val12 (rasv12) or the vector alone (V). After selection 
for 4 days, total protein was extracted, and PPP1CA expression was examined using 
western blot. The experiment was performed three independent times, and similar 
results were obtained. D) Quantification of the results obtained in the experiments 
performed in C. Left panel: average PPP1CA expression normalized to tubulin 
expression. Right panel: SPN level in WT MEFs. E) PP1 activity in Spn KO and WT 
MEFs. Exponentially growing MEFs from Spn KO mice and WT littermates at passage 
three were serum starved, and the PP1 phosphatase activity was measured. F) The data 
shown are the average from 20 Spn-KO clones and 20 WT clones. G) Inhibition of 
proteasome-mediated degradation increases the PPP1CA level in Spn-null cells. MEFs 
from Spn KO mice and WT littermates were grown and treated for 24 hrs with 10 nM 
MG132. Protein was extracted from cells at the same population doublings in all clones. 
PPP1CA expression was examined using western blot. Two independent Spn-null MEF 
 16 
clones and WT clones out of the ten clones analyzed for each genotype are shown. H) 
The data show the average measurements of ten Spn KO clones and ten WT clones. 
 
Figure 2. Lack of SPN increases Rb phosphorylation. A) Increased level of 
phosporylated Rb in Spn-null MEFs. Presenescent WT (+/+) and Spn-null (-/-) MEFs at 
passage two were grown in the presence of 10% FBS (+FBS). The cells were then 
serum starved for 24 hrs (0 h), after which 10% serum was added to the medium. 
Protein was extracted at the indicated time points. Total protein was resolved using 
PAGE, and Rb phosphorylated at Ser807/811 (pRb) was examined using western blot. 
The experiment was performed more than ten independent times, with similar results. 
B) Quantification of the experiment shown in A. The phosphorylated Rb level was 
normalized to the tubulin level in the same gel. Each point represents the average of five 
experiments, and the bars indicate the SD. C) DNA synthesis occurs more rapidly in 
Spn-null MEFs. Presenescent WT (+/+) and Spn-null (-/-) MEFs at passage two were 
grown in the presence of 10% FBS (+FBS). The cells were then serum starved for 24 
hrs (0 h), after which 10% serum was added to the medium, together with BrdU. The 
cells were harvested at different time points, and BrdU incorporation was quantified as 
indicated in the Materials and Methods. The experiment was performed three 
independent times, with similar results. D) Cyclin A is increased and activated early in 
Spn-null MEFs. Presenescent WT (+/+) and Spn-null (-/-) MEFs at passage two were 
grown in the presence of 10% FBS (+FBS). The cells were then serum starved for 24 
hrs (0 h), after which 10% serum was added to the medium. Protein was extracted at 
different time points following the addition of serum. Total protein was resolved using 
PAGE, and cyclin A expression was examined using western blot. E) Quantification of 
the results obtained in the experiments performed in D. The average cyclin A level was 
normalized to tubulin expression in three independent experiments; the bars indicate the 
SD.  
Figure 3. The absence of Spn protects from p16 loss by promoting p53 mutation 
during MEF immortalization. We generated multiple clones from WT (+/+), 
heterozygous (+/-), and Spn-null (-/-) MEFs and immortalized these cultures using 
standard 3T3 protocols. After immortalization at passage 11 and 12, total protein was 
extracted from each independent clone and resolved using PAGE. The expression of 
p53, p16, p19ARF, and tubulin was examined using western blot. The upper panels 
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show the results for WT (Spn (+/+)), heterozygous (Spn (+/-)), or Spn-null (Spn (-/-)) 
MEFs. The lower panels present the statistical analysis of the correlation between p53 
mutation, loss of p16 or p19ARF, and immortalization in the different clones. While we 
detected p53 mutations based on the stabilization of p53, all mutations were confirmed 
by sequencing p53 mRNA. 
Figure 4. Loss of Spn increases p53 activity. A) p53-null MEFs expressing the 
thermosensitive mutant p53val145 growing at 39°C were infected with a retrovirus 
expressing two independent Spn-specific shRNAs (Sh1 and Sh2) and selected. The cells 
were seeded in triplicate and cultured at 32°C. After 2 weeks, the colony number in 
each culture was quantified. The upper panel shows the reduction of the SPN level by 
the shRNAs. The bottom panel presents the number of colonies growing at 32°C. B) 
Presenescent WT (+/+) and Spn-null (-/-) MEFs at passage two were grown in the 
presence of 10% FBS. Etoposide (Eto) was then added to the medium for 24 hrs (24 h), 
and total protein was extracted. The expression of p53, p21, SPN, and tubulin was 
examined using western blot. The bar graphs present the quantification of the p53 and 
p21 levels. The experiment was performed three independent times, with similar results. 
C) Presenescent WT (+/+) and Spn-null (-/-) MEFs at passage two were grown in the 
presence of 10% FBS. 3-MC was then added, and total protein was extracted at 
different time points. The expression of p21 and tubulin was examined using western 
blot. The bar graphs show the quantification of the p21 level normalized to tubulin 
expression. The experiment was performed three independent times, with similar 
results. D) and E) Cohorts of 13–15 mice were intramuscularly injected with 3-MC, and 
the appearance of tumors and survival of the mice were monitored. The graphs show the 
survival of the different cohorts: WT (Spn (+/+)), heterozygous (Spn (+/-)) or Spn-null 
(Spn (-/-)) mice on a WT p53 background (D) or heterozygous p53 (p53 (+/-)) 
background (E). 
Figure 5. PPP1CA and ARF mediate SPN loss-dpendent p53 increase. A) 
Constitutive expression of PPP1CA inhibits the enhanced p53 activation resulting from 
the loss of Spn. Spn-null (-/-) and WT (+/+) MEFs were infected with a retrovirus 
expressing full-length PPP1CA (PPP1CA) or the vector alone (V). After selection, the 
cells were treated with 3-MC for 6 hrs or etoposide for 2 hrs, and the p53 levels were 
examined using western blot. The upper panel show the p53 and tubulin levels. The 
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bottom panel shows the quantification of one representative experiment out of three 
independent experiments. B) The loss of Spn increases p19ARF expression. Spn null (-
/-) and WT (+/+) MEFs were infected with a retrovirus expressing Hras-val12 
(RasV12), the p53 mutant 175H (p53DN), or the vector alone (V). After selection for 4 
days, the cells were serum starved, and the p53 level was examined using western blot. 
The upper panel presents the p19ARF and tubulin levels, while the lower panel presents 
a quantification of one representative experiment out of three independent experiments. 
C) The p19ARF-specific shRNA decreases p19ARF expression in Spn-null MEFs. 
MEFs were transfected with pRetrosuper encoding a p19ARF-specific shRNA and 
selected for 7 days. After selection, the cells were serum starved, and the p19ARF 
protein levels were analyzed using western blot. D) The loss of ARF abolishes p53-
enhanced induction following RasV12 expression. Wild-type (Spn (+/+)) or Spn-null 
(Spn (-/-)) MEFs expressing the p19ARF-specific shRNA or vector alone were infected 
with a retrovirus expressing oncogenic Ras or vector alone. After selection, the cells 
were serum starved, and the p53 and tubulin levels were examined. E) 
Immunofluoprescence demonstrating the lack of SPN and ARF colocalization. 
 
Figure 6. The absence of Spn on a p53-mutant background increases the 
tumorigenic potential of cells. A) p53-null MEFs expressing the thermosensitive 
mutant p53val145 growing at 39ºC were infected with a retrovirus vector carrying two 
independent Spn-specific shRNAs (Sh1 and Sh2) and selected. The cells were seeded in 
triplicate and grown at the permissive temperature (39ºC). After 1 week, the number of 
colonies in each culture was quantified. The graph shows the average colony number in 
three independent experiments. B) Immortalized WT (Spn +/+) and Spn-null (Spn-/-) 
MEF clones carrying mutations in p53 were seeded in triplicate at a low density and 
grown at 37ºC. The cells were then serum starved, and the cell number was determined. 
The experiment was performed three independent times, with similar results. C) 
Different immortalized MEF clones, with the indicated genetic alterations, were grown 
in the presence of 10% FBS. The cells were serum starved for 24 hrs (-FBS), after 
which 10% serum was added to the medium (+FBS, 0 h). The cell number was 
determined at the indicated time points. D) Focus formation assay following expression 
of the Ras or Ras+E1A oncogenes in immortalized MEF clones with the indicated 
genotypes. E: The overexpression of SPN reduces the growth of tumor cells. 
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